Oncology and Therapy

OCT 3, 2026 · JOURNAL ARTICLE

Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non–Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic Alterations

Oncology and Therapy

For patients with advanced/metastatic non–small cell lung cancer (aNSCLC) without actionable genomic alterations (AGAs) and with programmed death-ligand 1 (PD-L1) ≥ 50%, first-line

SEP 5, 2026 · JOURNAL ARTICLE

Real-World Testing Landscape and Costs of Companion Diagnostics and Comprehensive Genomic Profiling Across Nine Solid Tumors in Japan: A 10-Year Analysis

Oncology and Therapy

Retrospective real-world database analysis of testing utilization and costs across nine cancer types; descriptive findings on patterns and cost variation, but without comparative efficacy, clinical outcome, or causal inference.